Clinical Trial

The Efficacy and Safety of Sonrotoclax, Zanubrutinib Combined With Obinutuzumab in MCL

Name: The Efficacy and Safety of Sonrotoclax, Zanubrutinib Combined With Obinutuzumab in MCL — clinical trial record (NCT07548255)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting Phase 1

View on ClinicalTrials.gov →

Summary

A Single-Arm, Prospective Clinical Study Evaluating the Efficacy and Safety of Sonrotoclax, Zanubrutinib Combined with Obinutuzumab in the First-Line Treatment of Newly Diagnosed Intermediate-to-High-Risk Mantle Cell Lymphoma

Trial Details

NCT Number	NCT07548255
Lead Sponsor	Ruijin Hospital
Conditions	Intermediate-to-High-Risk Mantle Cell Lymphoma, the Efficacy and Safety
Enrollment	28 participants
Start Date	2026-04-20
Primary Completion	2029-03-01 (estimated)
Study Completion	2029-03-01 (estimated)
Updated on ClinicalTrials.gov	2026-04-23